Jane Street Group LLC Buys Shares of 16,605 Natera Inc (NASDAQ:NTRA)

Share on StockTwits

Jane Street Group LLC acquired a new position in Natera Inc (NASDAQ:NTRA) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 16,605 shares of the medical research company’s stock, valued at approximately $313,000.

Other hedge funds have also modified their holdings of the company. Northern Trust Corp raised its position in Natera by 1.5% during the first quarter. Northern Trust Corp now owns 375,674 shares of the medical research company’s stock valued at $3,483,000 after purchasing an additional 5,428 shares in the last quarter. State of Wisconsin Investment Board increased its holdings in shares of Natera by 30.4% in the second quarter. State of Wisconsin Investment Board now owns 30,000 shares of the medical research company’s stock worth $565,000 after buying an additional 7,000 shares during the period. Trexquant Investment LP increased its holdings in shares of Natera by 76.6% in the second quarter. Trexquant Investment LP now owns 22,643 shares of the medical research company’s stock worth $426,000 after buying an additional 9,820 shares during the period. State Board of Administration of Florida Retirement System purchased a new position in shares of Natera in the second quarter worth about $200,000. Finally, Paradigm Capital Management Inc. NY purchased a new position in shares of Natera in the second quarter worth about $207,000. Institutional investors own 67.46% of the company’s stock.

NTRA has been the topic of several recent analyst reports. Morgan Stanley raised their target price on Natera from $21.00 to $41.00 and gave the stock an “overweight” rating in a research note on Friday, September 28th. JPMorgan Chase & Co. initiated coverage on Natera in a research note on Friday, October 5th. They issued a “neutral” rating and a $26.00 target price on the stock. Canaccord Genuity raised their target price on Natera from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, August 16th. TheStreet raised Natera from a “d” rating to a “c-” rating in a research report on Thursday, August 9th. Finally, Craig Hallum lifted their price objective on Natera from $23.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Natera has an average rating of “Buy” and an average price target of $28.25.

Shares of NTRA stock traded down $3.83 during trading hours on Friday, hitting $16.80. 4,391,474 shares of the company’s stock traded hands, compared to its average volume of 457,138. Natera Inc has a 12-month low of $8.60 and a 12-month high of $29.62. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -7.00 and a beta of 2.11.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, November 8th. The medical research company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03). Natera had a negative return on equity of 752.93% and a negative net margin of 59.07%. The firm had revenue of $65.30 million during the quarter, compared to analysts’ expectations of $66.42 million. During the same quarter in the previous year, the firm earned ($0.51) earnings per share. Natera’s revenue was up 16.8% on a year-over-year basis. Analysts forecast that Natera Inc will post -2.02 earnings per share for the current year.

In other Natera news, insider Jonathan Sheena sold 166,667 shares of the business’s stock in a transaction on Friday, September 14th. The shares were sold at an average price of $24.27, for a total transaction of $4,045,008.09. Following the completion of the sale, the insider now directly owns 481,975 shares in the company, valued at approximately $11,697,533.25. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Matthew Rabinowitz sold 403,462 shares of the business’s stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $24.90, for a total transaction of $10,046,203.80. Following the sale, the chief executive officer now owns 1,701,686 shares of the company’s stock, valued at $42,371,981.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,014,988 shares of company stock valued at $48,674,710. 13.18% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Jane Street Group LLC Buys Shares of 16,605 Natera Inc (NASDAQ:NTRA)” was published by Equities Focus and is owned by of Equities Focus. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.equitiesfocus.com/2018/11/10/jane-street-group-llc-takes-position-in-natera-inc-ntra.html.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Recommended Story: What is a Tariff?

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply